# Aisling Capital Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1766721. Source: https://holderbook.com/funds/1766721-aisling-capital-management-lp/

- Reported value: $471.6M
- Positions: 14
- Weight of the ten largest: 99.0%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| BRIDGEBIO PHARMA INC | [BBIO](https://holderbook.com/stocks/BBIO/) | $341.8M | 4,589,611 | 72.5% | 29 |
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $37.6M | 1,555,664 | 8.0% | 21 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $28.8M | 1,316,806 | 6.1% | 26 |
| COMPASS PATHWAYS PLC | [CMPS](https://holderbook.com/stocks/CMPS/) | $20.3M | 1,432,336 | 4.3% | 12 |
| BICARA THERAPEUTICS INC | [BCAX](https://holderbook.com/stocks/BCAX/) | $16.9M | 568,919 | 3.6% | 8 |
| BRIDGEBIO ONCOLOGY THERAPEUT | [BBOT](https://holderbook.com/stocks/BBOT/) | $7.8M | 1,018,018 | 1.6% | 4 |
| SCHOLAR ROCK HLDG CORP | [SRRK](https://holderbook.com/stocks/SRRK/) | $4.2M | 77,031 | 0.9% | 4 |
| UROGEN PHARMA LTD | [URGN](https://holderbook.com/stocks/URGN/) | $4.0M | 108,000 | 0.8% | 3 |
| BIOMEA FUSION INC | [BMEA](https://holderbook.com/stocks/BMEA/) | $3.0M | 2,048,757 | 0.6% | 21 |
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $2.3M | 434,455 | 0.5% | 31 |
| EUPRAXIA PHARMACEUTICALS INC | [EPRX](https://holderbook.com/stocks/EPRX/) | $2.1M | 325,000 | 0.5% | 2 |
| VTV THERAPEUTICS INC | [VTVT](https://holderbook.com/stocks/VTVT/) | $1.9M | 50,000 | 0.4% | 1 |
| MARKER THERAPEUTICS INC | [MRKR](https://holderbook.com/stocks/MRKR/) | $478.3K | 325,370 | 0.1% | 13 |
| ONKURE THERAPEUTICS INC | [OKUR](https://holderbook.com/stocks/OKUR/) | $404.0K | 88,607 | 0.1% | 7 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +6.4% | +14.8% | -8.4% | 100% |
| Q1 2026 | -2.4% | -4.6% | +2.2% | 100% |
| Q4 2025 | +48.3% | +2.4% | +45.9% | 86% |
| Q3 2025 | +23.9% | +7.8% | +16.1% | 100% |
| Q2 2025 | +23.0% | +10.5% | +12.5% | 100% |
| Q1 2025 | +17.6% | -4.6% | +22.1% | 96% |
| Q4 2024 | +9.8% | +2.1% | +7.6% | 99% |
| Q3 2024 | +6.7% | +5.4% | +1.3% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $471.6M | 14 |
| Q1 2026 | $476.3M | 13 |
| Q4 2025 | $478.9M | 13 |
| Q3 2025 | $456.4M | 14 |
| Q2 2025 | $359.7M | 13 |
| Q1 2025 | $288.5M | 13 |
| Q4 2024 | $281.8M | 15 |
| Q3 2024 | $261.1M | 16 |
| Q2 2024 | $231.1M | 15 |
| Q1 2024 | $295.5M | 16 |
| Q4 2023 | $335.2M | 16 |
| Q3 2023 | $242.7M | 17 |